Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
Andreas Wollenberg(University Hospital Augsburg), Marius Ardeleanu(Regeneron (United States)), Thomas Hultsch(Sanofi (United States)), E. Rizova(Genesys (United States)), Brad Shumel(Regeneron (United States)), Q. Chen(Regeneron (United States)), Yuan Lü(Regeneron (United States)), Z. Chen(Regeneron (United States)), Neil M.H. Graham(UK Dementia Research Institute), Andrew Blauvelt(Veterans Health Administration), Lisa A. Beck(University of Rochester Medicine), Gianluca Pirozzi(Sanofi (United States)), Ana B. Rossi(Sanofi (United States)), Faisal A. Khokhar(Regeneron (United States)), Eric L. Simpson(Oregon Health & Science University)
Cited by 142
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Cytokine modulation of atopic dermatitis filaggrin skin expression
|Journal of Allergy and Clinical Immunology|2007|1.1k